During the third quarter, Commonwealth Equity Services LLC sold 237,049 shares of Novo Nordisk A/S, representing a 49.9% reduction in its position. Following the divestiture, the firm holds 237,978 shares, valued at approximately $13.2 million as of the end of the reporting period. This sizeable disposition marks one of the most significant single-investor adjustments in the quarter, and signals a notable shift in sentiment from a long-time holder of the Danish pharmaceutical leader.

Several smaller asset managers also altered their Novo Nordisk positions in recent quarters. True Wealth Design LLC boosted its stake by 209.8%, adding 300 shares to reach 443 shares; NewSquare Capital LLC increased its holdings by 174.1%, acquiring 282 shares for a total of 444 shares; Mid American Wealth Advisory Group and Maseco LLP each initiated new positions valued at approximately $37,000 and $39,000 respectively; and Copeland Capital Management LLC expanded its stake by 47.3%, purchasing 186 additional shares to hold 579 shares. Collectively, hedge funds and institutional investors now own 11.54% of the company’s outstanding stock, underscoring broad participation despite varying allocation decisions.

In the most recent quarter, Novo Nordisk reported earnings per share of $1.02, outperforming consensus estimates by $0.25, while generating revenue of $11.79 billion against analyst projections of $11.98 billion. The company achieved a return on equity of 73.5% and a net margin of 32.8%. Looking ahead, analysts surveyed by MarketBeat forecast full-year earnings of 3.84 per share and maintain a consensus rating of "Hold," with an average price target near $56.21. This convergence of strong profitability metrics and tempered revenue growth expectations will be critical for investors assessing Novo Nordisk’s valuation and growth trajectory.